Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Antibiotic

HHS Forges Unprecedented Partnership to Combat ‘Superbugs’ Resistance

Superbug definitionWashington, DC, July 29, 2016 ― To address one of the greatest modern threats to public health — antibiotic resistance — the U.S. Department of Health and Human Services (HHS), the Wellcome Trust of London, the AMR Centre of Alderley Park (Cheshire, United Kingdom), and Boston University School of Law will create one of the world’s largest public-private partnerships focused on preclinical discovery and development of new antimicrobial products.

Made possible through a cooperative agreement, the partnership promotes innovation and could provide hundreds of millions of dollars over five years to increase the number of antibiotics in the drug-development pipeline.

The Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, or CARB-X, represents a global innovation project for antibiotic products research and development. Continue reading

Rutgers Research: Experimental Antibiotic Treats Deadly MRSA Infection

Antibiotic 1New Brunswick, NJ, June 23, 2016 — A new experimental antibiotic developed by a team of scientists at Rutgers University successfully treats the deadly MRSA infection and restores the efficacy of a commonly prescribed antibiotic that has become ineffective against MRSA.

In research published in the July issue of Antimicrobial Agents and Chemotherapy, Rutgers scientists say that the combination of their newly developed antibiotic, TXA709, with cefdinir, an antibiotic that has been on the market for almost two decades, successfully treated the MRSA infection in animals. Continue reading

House Subcommittee Holds Hearing on Antibiotic-Resistant ‘Superbug’

Capitol Dome HEALTHCAREWashington, DC, June 15, 2016 ― Maria Rachal reports in The Hill that lawmakers on Capitol Hill are expressing growing alarm that a “superbug” crisis could strike the United States, with once treatable infections becoming lethal.

The House Energy and Commerce Subcommittee on Oversight and Investigations on June 14 grilled public health officials on how to best target funds at home and abroad against the threat.

The hearing came just weeks after a Pennsylvania woman became the first patient in America with MCR-1, a highly-resistant gene discovered in China last year.

“It signals the potential arrival of an unstoppable superbug,” said Rep. Fred Upton (R-Mich.) on Tuesday. Continue reading

CDC Reports that 1 in 3 Antibiotic Prescriptions Unnecessary

CDC LogoAtlanta, GA, May 4, 2016 ― At least 30 percent of antibiotics prescribed in the United States are unnecessary, according to new data published yesterday in the Journal of the American Medical Association (JAMA) by the Centers for Disease Control and Prevention (CDC), in collaboration with Pew Charitable Trusts and other public health and medical experts.

The study analyzed antibiotic use in doctors’ offices and emergency departments throughout the United States.

CDC researchers found that most of these unnecessary antibiotics are prescribed for respiratory conditions caused by viruses – including common colds, viral sore throats, bronchitis, and sinus and ear infections – which do not respond to antibiotics.

These 47 million excess prescriptions each year put patients at needless risk for allergic reactions or the sometimes deadly diarrhea, Clostridium difficile. Continue reading

HHS Sponsors New Broad Spectrum Antibiotic Development

HHS Logo blueWashington, DC, April 27, 2016 ― A broad spectrum antibiotic that could become the first of its kind to treat specific Gram negative and Gram positive infections as well as tularemia, a bioterrorism threat, will undergo the last steps in development with support from the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR).

Under an 18-month, $20 million agreement between ASPR’s Biomedical Advanced Research and Development Authority (BARDA) and Basilea Pharmaceutica International Ltd, the company will conduct Phase 3 clinical studies of the antibiotic, Ceftobiprole, in treating specific Gram-negative and Gram-positive infections. BARDA has the option to extend the agreement for up to a total of four-and-a-half years and up to a total of approximately $100 million.

The Phase 3 studies are necessary to apply for U.S. Food and Drug Administration (FDA) approval. In addition, Basilea will evaluate Ceftobiprole’s potential as a treatment for tularemia, which can cause deadly pneumonia infections and could be used as an agent of bioterrorism. Continue reading

Gov. Christie Signs Proclamation Recognizing ‘Get Smart About Antibiotics’ Week 2015

Antibiotics Week Get SmartTrenton, NJ, November 17, 2015 ― Antibiotics are powerful medicines used to combat life-threatening bacterial diseases, but overuse poses significant public health threats.

Get Smart About Antibiotics Week is an annual observance intended to educate the public about proper antibiotic use and prevention of antibiotic-resistant infections across all health care settings.

Gov. Chris Christie signed a proclamation recognizing Nov. 16 – 22 as Get Smart About Antibiotics Week in New Jersey. Continue reading

HHS Enters into Strategic Alliance to Accelerate New Antibiotic Development

Washington, DC, September 17, 2015 ― Multiple drugs to combat bioterrorism threats and other life-threatening bacterial infections will be developed under a public-private partnership agreement between the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) and AstraZeneca, a global biopharmaceutical company.

The partnership agreement with AstraZeneca uses Other Transaction Authority granted to the Secretary of HHS under the Pandemic and All Hazards Preparedness Act of 2006.   Continue reading

U.S. Senators Re-Introduce Bill to Speed Approval of Antibiotics

Lawrenceville, NJ, January 19, 2015 ― Pharmalot reports that, in the latest bid to combat antibiotic resistance, two U.S. senators have re-introduced legislation to create a so-called regulatory pathway to hasten approval of new treatments.

Known as the Promise for Antibiotics and Therapeutics for Health Act (PATH), the bill would accelerate approval for a serious or life-threatening condition that addresses an unmet medical need.  The PATH act would also require labeling to include a special FDA designation indicating intended use in limited, high-risk populations. Continue reading